Literature DB >> 7240342

Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma.

M E Heim, R Fiene, E Schick, E Wolpert, W Queisser.   

Abstract

Ten patients with advanced renal carcinoma were treated by ifosfamide (50-60 mg/kd/day x 5 days). The treatment was repeated every 4 weeks and continued until progression appeared. Two patients came into partial remission, two had subjective improvement, and six did not respond. Seven patients developed acute psychopathological symptoms during the first ifosfamide-cycle. Five patients had visual and paranoid hallucinations, four patients were completely confused. Follow-up for up to 10 weeks showed a persisting organic brain syndrome in five patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7240342     DOI: 10.1007/bf00405909

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  6 in total

1.  [Experience with fractionate massive-dose Ifosfamid therapy of generalized malignant tumors].

Authors:  H Hoefer-Janker; W Scheef; U Günther; W Hüls
Journal:  Med Welt       Date:  1975-05-16

2.  Pharmacokinetics of ifosfamide.

Authors:  L M Allen; P J Creaven
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

3.  Clinical pharmacology of isophosphamide.

Authors:  P J Creaven; L M Allen; D A Alford; M H Cohen
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

4.  Proceedings: Chemotherapy of adenocarcinoma of the kidney.

Authors:  R W Talley
Journal:  Cancer       Date:  1973-11       Impact factor: 6.860

5.  [Clinical experience with the cytostatic drug ifosfamide].

Authors:  S Ritter; H J Schröder
Journal:  Med Welt       Date:  1977-09-02

6.  [Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)].

Authors:  G Hartwich; B Neidhardt; H Lutz
Journal:  Med Klin       Date:  1978-09-08
  6 in total
  9 in total

1.  Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children.

Authors:  J Ninane; R Baurain; J de Kraker; A Ferster; A Trouet; G Cornu
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.

Authors:  J Boos; U Welslau; J Ritter; G Blaschke; G Schellong
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 3.  Common emergencies in cancer medicine: cardiovascular and neurologic syndromes.

Authors:  C R Thomas; E A Edmondson
Journal:  J Natl Med Assoc       Date:  1991-11       Impact factor: 1.798

4.  Nephrotoxicity associated with ifosfamide.

Authors:  J Smeitink; M Verreussel; C Schröder; R Lippens
Journal:  Eur J Pediatr       Date:  1988-11       Impact factor: 3.183

5.  A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix.

Authors:  R E Coleman; P G Harper; C Gallagher; R Osborne; E M Rankin; A C Silverstone; M L Slevin; R L Souhami; J S Tobias; C W Trask
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 6.  Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature.

Authors:  Karen I Sweiss; Rakesh Beri; Stacy S Shord
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

7.  Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.

Authors:  G G Steger; C Dittrich; O Schlappack; R Mader; C Herold; W P Brade; A Keller; K Moser
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 8.  Risk Factors for Ifosfamide-Related Encephalopathy in Adult Cancer Patients: An Integrative Review.

Authors:  Amanda Lee Brink; Christi Bowe; Joyce E Dains
Journal:  J Adv Pract Oncol       Date:  2020-05-01

9.  Ifosfamide-Induced Metabolic Encephalopathy in 2 Patients With Cutaneous T-Cell Lymphoma Successfully Treated With Methylene Blue.

Authors:  Anusha Vakiti; Ravi Pilla; Muhamad Alhaj Moustafa; Jacinth J Joseph; Aarthi G Shenoy
Journal:  J Investig Med High Impact Case Rep       Date:  2018-07-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.